Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Published:2019-03-01 Issue:3 Volume:5 Page:376
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Toi Yukihiro¹,Sugawara Shunichi¹,Sugisaka Jun¹,Ono Hirotaka¹,Kawashima Yosuke¹,Aiba Tomoiki¹,Kawana Sachiko¹,Saito Ryohei¹,Aso Mari¹,Tsurumi Kyoji¹,Suzuki Kana¹,Shimizu Hisashi¹,Domeki Yutaka¹,Terayama Keisuke¹,Nakamura Atsushi¹,Yamanda Shinsuke¹,Kimura Yuichiro¹,Honda Yoshihiro¹

Affiliation:

1. Department of Pulmonary Medicine, Sendai Kousei Hospital, Aoba-ku, Sendai, Miyagi, Japan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/3/376/17345785/jamaoncology_toi_2018_oi_180104.pdf

Reference41 articles.

1. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma.;Ribas;JAMA,2016

2. Pembrolizumab for the treatment of non-small-cell lung cancer.;Garon;N Engl J Med,2015

3. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.;Parry;Mol Cell Biol,2005